Kinetics of macromolecules injected into the subretinal space

doi:10.1016/0014-4835(85)90138-1

Experimental Eye Research

Volume 40, Issue 5, May 1985, Pages 687-696

https://doi.org/10.1016/0014-4835(85)90138-1 Get rights and content

Abstract

Small, experimental, non-rhegmatogenous retinal detachments (blebs) in rabbit eyes resorbed 50% more slowly when filled with autologous serum than with Hanks' solution. To study the fate of large molecules in the subretinal space, carboxyfluorescein and several sizes of FITC-dextrans were injected into blebs and their movement followed by fluorophotometry.

Carboxyfluorescein diffused quickly into the vitreous and was gone from the space after 8 hr. FITC-dextran 10-S (smaller than albumin) also diffused readily into the vitreous and took about 30 hr to be eliminated from the subretinal space. The diffusion of FITC-dextran 70-S and 150-S (both larger than albumin) was markedly slower, and roughly 80% of the 150-S was still present in the subretinal space after 3 days. Since the subretinal fluid in all of these blebs resorbed within 10 hr, the physiologic mechanisms for fluid resorption and elimination of large substances appear to be independent. Damaging the RPE barrier with sodium iodate allowed even the larger FITC-dextrans to exit from the subretinal space.

References (22)

M.B. Bellhorn et al.
Permeability of fluorescein-labelled dextrans in fundus fluorescein angiography of rats and birds
Exp. Eye Res.
(1977)
F. Johnson et al.
A simple method of measuring aqueous humor flow with intravitreal fluoresceinated dextrans
Exp. Eye Res.
(1984)
U. Schröder et al.
Stability of fluorescein labelled dextrans in vivo and in vitro
Microvasc. Res.
(1976)
J.G. Tonus et al.
Neuro-glial relationships at the external limiting membrane of the newt retina
Exp. Eye Res.
(1979)
K. Asayama
In vivo study on the absorption of the subretinal fluid. 2. Studies on an absorption of tracers injected between the sensory retina and the pigment epithelium layer
Acta Soc. Ophthalmol. Jpn
(1976)
R.W. Bellhorn et al.
Experimental retinal edema
Invest. Ophthalmol. Vis. Sci.
(1984)
A. Bill
Some aspects of tissue fluid dynamics in the eye
J.G. Cunha-Vaz et al.
The active transport of fluorescein by the retinal vessels and the retina
J. Physiol.
(1967)
D.A. Frambach et al.
The rate and route of fluid resorption from the subretinal space of the rabbit
Invest. Ophthalmol. Vis. Sci.
(1982)
P. Grimes et al.
Carboxyfluorescein. A probe of the blood-ocular barriers with lower membrane permeability than fluorescein
Arch. Ophthalmol.
(1982)

V.E. Kinsey et al.

Chemistry and dynamics of aqueous humor

Cited by (77)

Non-vasogenic cystoid maculopathies
2022, Progress in Retinal and Eye Research
Besides cystoid macular edema due to a blood-retinal barrier breakdown, another type of macular cystoid spaces referred to as non-vasogenic cystoid maculopathies (NVCM) may be detected on optical coherence tomography but not on fluorescein angiography. Various causes may disrupt retinal cell cohesion or impair retinal pigment epithelium (RPE) and Müller cell functions in the maintenance of retinal dehydration, resulting in cystoid spaces formation. Tractional causes include vitreomacular traction, epiretinal membranes and myopic foveoschisis. Surgical treatment does not always allow cystoid space resorption. In inherited retinal dystrophies, cystoid spaces may be part of the disease as in X-linked retinoschisis or enhanced S-cone syndrome, or occur occasionally as in bestrophinopathies, retinitis pigmentosa and allied diseases, congenital microphthalmia, choroideremia, gyrate atrophy and Bietti crystalline dystrophy. In macular telangiectasia type 2, cystoid spaces and cavitations do not depend on the fluid leakage from telangiectasia. Various causes affecting RPE function may result in NVCM such as chronic central serous chorioretinopathy and paraneoplastic syndromes. Non-exudative age macular degeneration may also be complicated by intraretinal cystoid spaces in the absence of fluorescein leakage. In these diseases, cystoid spaces occur in a context of retinal cell loss. Various causes of optic atrophy, including open-angle glaucoma, result in microcystoid spaces in the inner nuclear layer due to a retrograde transsynaptic degeneration. Lastly, drug toxicity may also induce cystoid maculopathy. Identifying NVCM on multimodal imaging, including fluorescein angiography if needed, allows guiding the diagnosis of the causative disease and choosing adequate treatment when available.
Vitrectomy with subretinal tissue plasminogen activator (r-TPA) and intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) for submacular hemorrhages treatment: Retrospective analysis of 22 cases
2022, Archivos de la Sociedad Espanola de Oftalmologia
Las hemorragias maculares suponen una complicación severa de otras patologías retinianas, como la degeneración macular asociada a la edad (DMAE) o los macroaneurismas. El abordaje terapéutico de las mismas no se encuentra estandarizado, pudiendo variar desde la observación hasta el tratamiento quirúrgico.
Análisis retrospectivo de 22 casos de hemorragia macular, tratados mediante vitrectomías asociada a rTPA subretiniano y antiVEGF intravítreo durante un período de cinco años.
Se incluyeron 22 ojos de 22 pacientes, de los que 12 (52%) eran mujeres. La edad media al diagnóstico fue de 84,4 años. Del total de pacientes, 13 eran pseudofáquicos (54,1%) y 19 (86,36%) presentaban comorbilidades oftalmológicas previas. La etiología de las hemorragias maculares fue DMAE en 19 pacientes (86,36%). La media de mejor agudeza visual (AV) corregida al diagnóstico fue de 24,55 (puntuación Early Treatment Diabetic Retinopathy Study - ETDRS), con una mejoría estadísticamente significativa a 36,78 a los tres meses de la cirugía (p = 0,011). Con un promedio de 23,5 meses de seguimiento, no se observaron diferencias en el pronóstico asociadas a etiología o tamaño de la hemorragia.
El tratamiento de las hemorragias maculares mediante vitrectomía, rTPA subretiniano y antiVEGF mejora el pronóstico visual de los pacientes afectos.
Macular hemorrhages are a severe complication of other retinal pathologies, such as age-related macular degeneration (AMD) or macroaneurysms. Their therapeutic approach is not standardized, and can vary from observation to surgical treatment.
Retrospective analysis of 22 cases of macular hemorrhage, treated with vitrectomy associated to subretinal rTPA and intravitreal anti-VEGF over a period of 5 years.
22 eyes of 22 patients were included, of which 12 (52%) were women. The mean age at diagnosis was 84.4 years. 13 patients were pseudophakic (54.1%) and 19 (86.36%) had previous ophthalmological comorbidities. The etiology of the macular hemorrhage was AMD in 19 patients (86.36%). The mean of best VA corrected at diagnosis was 24.55 (Early Treatment Diabetic Retinopathy Study score -ETDRS), with a statistically significant improvement to 36.78 3 months after surgery (p = 0.011). With an average of 23.5 months of follow-up, no differences in prognosis associated with the etiology or size of the hemorrhage were observed.
The treatment of macular hemorrhages by vitrectomy, subretinal rTPA and antiVEGF improves the visual prognosis of affected patients.
Mechanisms of macular edema: Beyond the surface
2018, Progress in Retinal and Eye Research
Citation Excerpt :
Indeed, after subretinal injection, FITC-dextran 10S (Stokes radius: 23 Å) diffuses rapidly into the vitreous, but 70S- and 150S- dextrans (Stokes radius: 60 and 85 Å, respectively) mostly remain in the subretinal space due to the OLM barrier (Marmor et al., 1985). The kinetics of water and macromolecules injected under the macula has never been studied and could show significant differences with kinetics observed in animal models lacking a macula (Marmor et al., 1985), related to the specific cellular architecture and physiology of the macula. Movement of molecules between photoreceptors might be influenced, depending on their physico-chemical properties, by interactions with glycosaminoglycans and glycoproteins in the interphotoreceptor matrix.
Macular edema consists of intra- or subretinal fluid accumulation in the macular region. It occurs during the course of numerous retinal disorders and can cause severe impairment of central vision. Major causes of macular edema include diabetes, branch and central retinal vein occlusion, choroidal neovascularization, posterior uveitis, postoperative inflammation and central serous chorioretinopathy. The healthy retina is maintained in a relatively dehydrated, transparent state compatible with optimal light transmission by multiple active and passive systems. Fluid accumulation results from an imbalance between processes governing fluid entry and exit, and is driven by Starling equation when inner or outer blood-retinal barriers are disrupted. The multiple and intricate mechanisms involved in retinal hydro-ionic homeostasis, their molecular and cellular basis, and how their deregulation lead to retinal edema, are addressed in this review. Analyzing the distribution of junction proteins and water channels in the human macula, several hypotheses are raised to explain why edema forms specifically in the macular region. “Pure” clinical phenotypes of macular edema, that result presumably from a single causative mechanism, are detailed. Finally, diabetic macular edema is investigated, as a complex multifactorial pathogenic example. This comprehensive review on the current understanding of macular edema and its mechanisms opens perspectives to identify new preventive and therapeutic strategies for this sight-threatening condition.
Overcoming ocular drug delivery barriers through the use of physical forces
2018, Advanced Drug Delivery Reviews
Overcoming the physiological barriers in the eye remains a key obstacle in the field of ocular drug delivery. While ocular barriers naturally have a protective function, they also limit drug entry into the eye. Various pharmaceutical strategies, such as novel formulations and physical force-based techniques, have been investigated to weaken these barriers and transport therapeutic agents effectively to both the anterior and the posterior segments of the eye. This review summarizes and discusses the recent research progress in the field of ocular drug delivery with a focus on the application of physical methods, including electrical fields, sonophoresis, and microneedles, which can enhance penetration efficiency by transiently disrupting the ocular barriers in a minimally or non-invasive manner.
Nanotechnology-based strategies for treatment of ocular disease
2017, Acta Pharmaceutica Sinica B
Citation Excerpt :
As a result the ocular disease related biomarkers should be fully understood as well as the cellular and molecular mechanism of their functions. ( 4) It is reported that nanoparticles seem to grow in size and aggregate inside the tissues after intravitreous injection or other administration route33–35. This phenomenon could decrease the delivery efficiency and affect drug distribution.
Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers and pharmacologists. Although there are conventional noninvasive and invasive treatments, such as eye drops, injections and implants, the current treatments either suffer from low bioavailability or severe adverse ocular effects. Alternatively, the emerging nanoscience and nanotechnology are playing an important role in the development of novel strategies for ocular disease therapy. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and intimately interact with specific ocular tissues. In this review, we highlight the recent attempts of nanotechnology-based systems for imaging and treating ocular diseases, such as corneal d iseases, glaucoma, retina diseases, and choroid diseases. Although additional work remains, the progress described herein may pave the way to new, highly effective and important ocular nanomedicines.
Pharmacokinetic aspects of retinal drug delivery
2017, Progress in Retinal and Eye Research
Citation Excerpt :
Carboxyfluorescein and FITC-dextran 10-S diffused quickly into the vitreous and disappeared in 8 and 30 h, respectively. However, diffusion of FITC-dextran 70-S and 150-S (both larger than albumin) was slow, and about 80% of the 150-S was still in the sub-retinal space after 3 days (Marmor et al., 1985). Table 2 shows information about the permeation of various macromolecules across the OLM in the rabbits suggesting that the molecular weight cut-off is about the size of an albumin molecule (Bunt-Milam et al., 1985).
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.

View all citing articles on Scopus

: Presented in part at the annual meeting of the association for Research in Vision and Ophthalmology, Sarasota, Florida, 3 May 1984.

View full text

Kinetics of macromolecules injected into the subretinal space

Abstract

Exp. Eye Res.

Exp. Eye Res.

Microvasc. Res.

Exp. Eye Res.

In vivo study on the absorption of the subretinal fluid. 2. Studies on an absorption of tracers injected between the sensory retina and the pigment epithelium layer

Acta Soc. Ophthalmol. Jpn

Experimental retinal edema

Invest. Ophthalmol. Vis. Sci.

Some aspects of tissue fluid dynamics in the eye

The active transport of fluorescein by the retinal vessels and the retina

J. Physiol.

The rate and route of fluid resorption from the subretinal space of the rabbit

Invest. Ophthalmol. Vis. Sci.

Carboxyfluorescein. A probe of the blood-ocular barriers with lower membrane permeability than fluorescein

Arch. Ophthalmol.

Chemistry and dynamics of aqueous humor